<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction - Pouwer, AW - 2015 | Cochrane Library</title> <meta content="Long‐acting FSH versus daily FSH for women undergoing assisted reproduction - Pouwer, AW - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009577.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Long‐acting FSH versus daily FSH for women undergoing assisted reproduction - Pouwer, AW - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009577.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009577.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Long‐acting FSH versus daily FSH for women undergoing assisted reproduction" name="citation_title"/> <meta content="Annefloor W Pouwer" name="citation_author"/> <meta content="Rijnstate Hospital" name="citation_author_institution"/> <meta content="annefloorpouwer@hotmail.com" name="citation_author_email"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Jan AM Kremer" name="citation_author"/> <meta content="Radboud University Nijmegen Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009577.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/07/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009577.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009577.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009577.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Delayed‐Action Preparations [administration &amp; dosage]; Fertilization in Vitro [*methods]; Follicle Stimulating Hormone [*administration &amp; dosage]; Follicle Stimulating Hormone, Human [administration &amp; dosage]; Hormones [*administration &amp; dosage]; Live Birth; Luteinizing Hormone [*administration &amp; dosage]; Ovulation Induction; Randomized Controlled Trials as Topic; Recombinant Proteins [administration &amp; dosage]; Sperm Injections, Intracytoplasmic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009577.pub3&amp;doi=10.1002/14651858.CD009577.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009577\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009577\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009577.pub3",title:"Long\\u2010acting FSH versus daily FSH for women undergoing assisted reproduction",firstPublishedDate:"Jul 14, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009577.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009577.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009577.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009577.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009577.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009577.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009577.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009577.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009577.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009577.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2063 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009577.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0125"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-sec-0119"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/appendices#CD009577-sec-0130"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/table_n/CD009577StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/table_n/CD009577StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#CD009577-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Annefloor W Pouwer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#CD009577-cr-0003">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information#CD009577-cr-0004">Jan AM Kremer</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information/en#CD009577-sec-0187">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 July 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009577.pub3">https://doi.org/10.1002/14651858.CD009577.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009577-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009577-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009577-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009577-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009577-abs-0001" lang="en"> <section id="CD009577-sec-0001"> <h3 class="title" id="CD009577-sec-0001">Background</h3> <p>Assisted reproduction techniques (ART), such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), can help subfertile couples to create a family. It is necessary to induce multiple follicles, which is achieved by follicle stimulating hormone (FSH) injections. Current treatment regimens prescribe daily injections of FSH (urinary FSH either with or without luteinizing hormone (LH) injections or recombinant FSH (rFSH)). </p> <p>Recombinant DNA technologies have produced a new recombinant molecule which is a long‐acting FSH, named corifollitropin alfa (Elonva) or FSH‐CTP. A single dose of long‐acting FSH is able to keep the circulating FSH level above the threshold necessary to support multi‐follicular growth for an entire week. The optimal dose of long‐acting FSH is still being determined. A single injection of long‐acting FSH can replace seven daily FSH injections during the first week of controlled ovarian stimulation (COS) and can make assisted reproduction more patient friendly. </p> </section> <section id="CD009577-sec-0002"> <h3 class="title" id="CD009577-sec-0002">Objectives</h3> <p>To compare the effectiveness of long‐acting FSH versus daily FSH in terms of pregnancy and safety outcomes in women undergoing IVF or ICSI treatment cycles. </p> </section> <section id="CD009577-sec-0003"> <h3 class="title" id="CD009577-sec-0003">Search methods</h3> <p>We searched the following electronic databases, trial registers and websites from inception to June 2015: the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialized Register, MEDLINE, EMBASE, PsycINFO, CINAHL, electronic trial registers for ongoing and registered trials, citation indexes, conference abstracts in the ISI Web of Knowledge, LILACS, Clinical Study Results (for clinical trial results of marketed pharmaceuticals), PubMed and OpenSIGLE. We also carried out handsearches. </p> </section> <section id="CD009577-sec-0004"> <h3 class="title" id="CD009577-sec-0004">Selection criteria</h3> <p>We included all randomised controlled trials (RCTs) comparing long‐acting FSH versus daily FSH in women who were part of a couple with subfertility and undertaking IVF or ICSI treatment cycles with a GnRH antagonist or agonist protocol. </p> </section> <section id="CD009577-sec-0005"> <h3 class="title" id="CD009577-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed study selection, data extraction and assessment of risk of bias. We contacted trial authors in cases of missing data. We calculated risk ratios for each outcome, and our primary outcomes were live birth rate and ovarian hyperstimulation syndrome (OHSS) rate. Our secondary outcomes were ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, any other adverse event (including ectopic pregnancy, congenital malformations, drug side effects and infection) and patient satisfaction with the treatment. Trials reported all outcomes, except patient satisfaction with the treatment. </p> </section> <section id="CD009577-sec-0006"> <h3 class="title" id="CD009577-sec-0006">Main results</h3> <p>We included six RCTs with a total of 3753 participants and we graded the quality of the included studies as moderate. All studies included women with an indication for COS as part of an IVF/ICSI cycle with age ranging from 18 to 41 years. A comparison of long‐acting FSH versus daily FSH did not show evidence of difference in effect on overall live birth rate (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.84 to 1.07; 2363 participants, five studies; I² statistic = 44%) or OHSS (RR 1.00, 95% CI 0.74 to 1.37; 3753 participants, six studies; I² statistic = 0%). We compared subgroups by dose of long‐acting FSH. There was evidence of a reduced live birth rate in women who received lower doses (60 to 120 μg) of long‐acting FSH compared to daily FSH (RR 0.70, 95% CI 0.52 to 0.93; 645 participants, three studies; I² statistic = 0%). There was no evidence a difference between the groups in live births in the medium dose (150 to 180 μg) subgroup (RR 1.03, 95% CI 0.90 to 1.18; 1685 participants, four studies; I² statistic = 6%). There was no evidence of a difference between the groups in the clinical pregnancy rate (any dose), ongoing pregnancy rate (any dose), multiple pregnancy rate (any dose), miscarriage rate (low or medium dose), ectopic pregnancy rate (any dose), congenital malformation rate, congenital malformation rate; major or minor (low or medium dose). </p> </section> <section id="CD009577-sec-0007"> <h3 class="title" id="CD009577-sec-0007">Authors' conclusions</h3> <p>The use of a medium dose (150 to 180 μg) of long‐acting FSH is a safe treatment option and equally effective compared to daily FSH in women with unexplained subfertility. There was evidence of reduced live birth rate in women receiving a low dose (60 to 120 μg) of long‐acting FSH compared to daily FSH. Further research is needed to determine whether long‐acting FSH is safe and effective for use in hyper‐ or poor responders and in women with all causes of subfertility. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009577-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009577-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009577-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009577-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009577-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009577-abs-0003" lang="en"> <h3>Long‐acting FSH versus daily FSH for women undergoing assisted reproduction</h3> <p><b>Review question</b> </p> <p>The aim of this Cochrane review was to compare the effectiveness and safety of weekly (long‐acting) follicle stimulating hormone (FSH) compared to daily FSH in women undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatment cycles.<br/> <br/> <b>Background</b> </p> <p>When assisted reproduction techniques such as IVF and ICSI are performed, the fertilisation of the egg takes place outside the woman's body. Multiple eggs are needed to increase the availability of fertilised eggs. The growth of multiple eggs is achieved by stimulation of the ovary with FSH. There is a risk of overstimulation (ovarian hyperstimulation syndrome or OHSS). OHSS is a serious adverse effect which can cause illness or death. </p> <p>Current treatment regimens to stimulate the growth of multiple eggs prescribe daily injections of FSH during the first seven days of treatment. A new treatment is now available which replaces these injections with just a single injection. This new treatment can be more patient friendly, as daily injections may cause discomfort and be a physical burden to the women. </p> <p><b>Study characteristics</b> </p> <p>We included six randomised controlled trials comparing weekly versus daily FSH in 3753 women undertaking controlled ovarian stimulation as part of an IVF/ICSI cycle. Their age ranged from 18 to 41 years. The studies used different dosages of weekly FSH ranging from 60 to 240 μg. Five studies reported live birth rate and all six studies reported OHSS rate (our primary outcomes). The evidence is current to June 2015. </p> <p><b>Key results</b> </p> <p>There was no evidence of a difference in live birth rates between medium dose (150 to 180 μg) weekly FSH and daily FSH. There was evidence of a reduced live birth rate in women who received lower doses (60 to 120 μg) of weekly FSH when compared to daily FSH. Only one study used a high dose of weekly FSH, so we cannot make conclusions about this dosage group.There was no evidence of a difference between the groups in OHSS rate. We concluded that medium dose (150 to 180 μg) weekly FSH is a safe treatment option and is as effective in terms of life birth rate as daily FSH injections. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence was graded as moderate. Five out of six studies were funded by the same drug manufacturer. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009577-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009577-sec-0125"></div> <h3 class="title" id="CD009577-sec-0126">Implications for practice</h3> <section id="CD009577-sec-0126"> <p>The use of a medium dose (150 to 180 μg) of long‐acting FSH is a safe treatment option and equally effective compared to daily FSH. </p> </section> <h3 class="title" id="CD009577-sec-0127">Implications for research</h3> <section id="CD009577-sec-0127"> <p>All current trials excluded poor‐ and hyper‐responders to ovarian stimulation and women with explained subfertility. Therefore, further research is needed to determine if long‐acting FSH can be used in all women with subfertility. There is one ongoing trial about long‐acting FSH in combination with a GnRH agonist treatment (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). More research is needed to determine the pregnancy and safety outcomes in this treatment combination. There are no studies about patient satisfaction with the treatment and further research should examine this to determine whether the new treatment is more patient friendly than the daily injections regimen. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009577-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009577-sec-0015"></div> <div class="table" id="CD009577-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient:</b> Women undergoing assisted reproduction </p> <p><b>Settings:</b> clinic<br/> <b>Intervention:</b> Long‐acting FSH (all doses) </p> <p><b>Control:</b> daily FSH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Daily FSH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long‐acting FSH (all doses) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ Low dose (60 to 120 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> <br/> (183 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.7</b> <br/> (0.52 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ Medium dose (150 to 180 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> <br/> (229 to 301) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.9 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1685<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ High dose (240 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> <br/> (45 to 570) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.12 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ Low dose (60 to 120 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (26 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.56 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ Medium dose (150 to 180 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> <br/> (43 to 85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.68 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3075<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ High dose (240 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.73</b> <br/> (0.09 to 32.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision, due to low event rate<br/> <sup>2</sup> Downgraded one level as two studies (including the largest study) at high risk of attrition bias<br/> <sup>3</sup> Downgraded two levels for imprecision due to very low event rate and downgraded a further level for high risk of attrition bias </p> <p><sup>4</sup> Downgraded for imprecision as confidence intervals compatible with clinically meaningful benefit in either arm or with no effect </p> <p><sup>5</sup> Downgraded for imprecision as confidence intervals compatible with clinically meaningful benefit in either arm or with no effect, and downgraded a further level for high risk of attrition bias in two studies </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009577-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009577-sec-0016"></div> <p>For definitions of terminology see the Glossary (<a href="./appendices#CD009577-sec-0131">Appendix 1</a>). </p> <section id="CD009577-sec-0017"> <h3 class="title" id="CD009577-sec-0017">Description of the condition</h3> <p>Infertility affects 10% to 15% of couples trying to conceive (<a href="./references#CD009577-bbs2-0024" title="EversJLH . Female subfertility. Lancet2002;360(9327):151‐9. ">Evers 2002</a>; <a href="./references#CD009577-bbs2-0026" title="GnothC , GodehardtE , Frank‐HerrmannP , FriolK , TiggesJ , FreundlG . Definition and prevalence of subfertility and infertility. Human Reproduction2005;20(5):1144‐7. ">Gnoth 2005</a>). Assisted reproduction techniques (ART), such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), can help these couples to create a family. In ART it is necessary to induce multiple follicles. This is achieved by controlled ovarian stimulation (COS) with follicle stimulating hormone (FSH) injections. </p> <p>Current treatment regimens prescribe daily injections of FSH (urinary FSH with or without luteinizing hormone (LH) injections or recombinant FSH (rFSH)). The FSH injections are usually started from cycle day two. Prevention of a premature ovulation due to a LH surge can be accomplished with gonadotropin‐releasing hormone (GnRH) agonists or GnRH antagonists. GnRH agonists (GnRHa) are the most commonly used adjuvants for COS (<a href="./references#CD009577-bbs2-0035" title="Tur‐KaspaI , FauserB . The use of GnRH agonist in IVF protocols. IVF Worldwide website accessed 20 May 2015:http://www.ivf‐worldwide.com/survey/the‐use‐of‐gnrh‐agonist‐in‐ivf‐protocols/results‐the‐use‐of‐gnrh‐agonist‐in‐ivf‐protocols.html. ">Tur‐Kaspa</a>) <a href="./references#CD009577-bbs2-0030" title="MaheshwariA , GibreelA , SiristatidisCS , BhattacharyaS . Gonadotrophin‐releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD006919.pub3] ">Maheshwari 2011</a> reported no evidence of a statistically significant difference in live birth rate amongst various protocols (long, short or ultrashort) of GnRHa for pituitary down‐regulation in assisted reproduction treatments. Some clinicians consider antagonists to be the first choice in COS due to their immediate action, lack of side effects (e.g. lower incidence of ovarian hyperstimulation syndrome (OHSS)), the need for fewer injections and the same live birth rate as with agonists (<a href="./references#CD009577-bbs2-0020" title="Al‐InanyHG , YoussefMAFM , AboulgharM , BroekmansFJ , SterrenburgMD , SmitJG , et al. Gonadotrophin‐releasing hormone antagonists for assisted reproductive technology. Cochrane Database of Systematic Reviews2011, Issue 5. [DOI: 10.1002/14651858.CD001750.pub3] ">Al‐Inany 2011</a>; <a href="./references#CD009577-bbs2-0034" title="TarlatzisBC , KolibianakisEM . GnRH agonists vs antagonists. Best Practice &amp; Research. Clinical Obstetrics and Gynaecology2007;21(1):57‐65. ">Tarlatzis 2007</a>). Antagonist injections start on day five or six (see <a href="#CD009577-fig-0001">Figure 1</a>) whereas agonist injections in a long protocol start two to four weeks prior to the stimulation (see <a href="#CD009577-fig-0002">Figure 2</a>). Short and ultrashort GnRHa protocols start at day 1 or 2. </p> <div class="figure" id="CD009577-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH antagonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH antagonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> </div> <div class="figure" id="CD009577-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH agonist protocol (Source:de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH agonist protocol (Source:<a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> </div> <p>FSH and GnRH agonist or antagonist injections are continued up to and including the day the leading follicle reaches 18 to 20 mm (<a href="./references#CD009577-bbs2-0027" title="HeinemanMJ , EversJLH , MassugerLFAG , SteegersEAP . Obstetrie en Gynaecology. De voortplanting van de mens. Amsterdam: Elsevier Gezondheidszorg, 2007. ">Heineman 2007</a>). Then, ovulation is induced by a human chorionic gonadotropin (hCG) injection (see <a href="#CD009577-fig-0001">Figure 1</a> and <a href="#CD009577-fig-0002">Figure 2</a>). Two days (34 to 36 hours) later, several oocytes are ready for ovum pick‐up. After the pick‐up, the oocytes are fertilised by IVF or ICSI. One, two or sometimes three embryos are transferred two to five days later (<a href="./references#CD009577-bbs2-0029" title="KovacsG . How to Improve your ART Success Rates. An Evidence‐Based Review of Adjuncts to IVF. Cambridge: Cambridge University Press, 2011. ">Kovacs 2011</a>). </p> </section> <section id="CD009577-sec-0018"> <h3 class="title" id="CD009577-sec-0018">Description of the intervention</h3> <p>Daily injections of daily FSH are required to maintain steady‐state levels of FSH in the blood that are above the threshold for follicular development and ongoing maturation, due to its relatively short half‐life and rapid metabolic clearance (<a href="./references#CD009577-bbs2-0023" title="DuijkersIJ , KlippingC , BoerrigterPJ , MachielsenCS , DeBieJJ , VoortmanG . Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long‐acting recombinant FSH preparation (FSH‐CTP) in healthy pituitary‐suppressed females. Human Reproduction2002;17(8):1987‐93. ">Duijkers 2002</a>). The daily subcutaneous administration and side effects of the daily FSH preparations can cause discomfort and be a physical burden to the patient. Many couples withdraw prematurely from IVF or ICSI due to emotional distress, which limits their chances of pregnancy. A study showed withdrawal of 40% of non‐pregnant couples after just one cycle of IVF due to emotional distress (<a href="./references#CD009577-bbs2-0033" title="SchröderAK , KatalinicA , DiedrichK , LudwigM . Cumulative pregnancy rates and drop‐out rates in a German IVF programme: 4102 cycles in 2130 patients. Reproductive Biomedicine Online2004;8(5):600‐6. ">Schröder 2004</a>). For this reason, a patient‐friendly therapy regimen should be developed. </p> <p>Recombinant DNA technologies have produced a new recombinant molecule which consists of the α‐subunit of human FSH and a hybrid subunit consisting of the carboxyl‐terminal peptide of the β‐subunit of human chorionic gonadotrophin (hCG) coupled with the FSH β‐subunit. This molecule is a long‐acting FSH, named corifollitropin alfa (Elonva) or FSH‐CTP (<a href="./references#CD009577-bbs2-0025" title="FauserBC , MannaertsBM , DevroeyP , LeaderA , BoimeI , BairdDT . Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle‐stimulating activity and reduced injection frequency. Human Reproduction Update2009;15(3):309‐21. ">Fauser 2009</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). A single injection of long‐acting FSH on the first day of the stimulation can replace the first seven daily injections of daily FSH and fewer injections can make assisted reproduction more acceptable to these women. </p> <p>The administration of long‐acting FSH involves one subcutaneous injection on the first day of COS. The dose of long‐acting FSH should be as low as possible to avoid OHSS but high enough to support COS over the seven days. <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a> investigated 100 µg for women weighing less than 60 kg and 150 µg for women weighing over 60 kg and the doses were proven to be adequate. The optimal dose of long‐acting FSH is still under investigation. From day seven, the same treatment protocol as daily FSH is used (see <a href="#CD009577-fig-0003">Figure 3</a>; <a href="#CD009577-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD009577-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH antagonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH antagonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> </div> <div class="figure" id="CD009577-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH agonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH agonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> </div> </section> <section id="CD009577-sec-0019"> <h3 class="title" id="CD009577-sec-0019">How the intervention might work</h3> <p>Long‐acting FSH has, compared with daily FSH, an approximately two‐fold longer elimination half‐life and an almost four‐fold extended time to peak serum levels (<a href="./references#CD009577-bbs2-0022" title="DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , IJzerman‐BoonPC , FauserBCJM , the ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. ">Devroey 2009</a>; <a href="./references#CD009577-bbs2-0023" title="DuijkersIJ , KlippingC , BoerrigterPJ , MachielsenCS , DeBieJJ , VoortmanG . Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long‐acting recombinant FSH preparation (FSH‐CTP) in healthy pituitary‐suppressed females. Human Reproduction2002;17(8):1987‐93. ">Duijkers 2002</a>). Due to this pharmacokinetic profile, a single dose of long‐acting FSH is able to keep the circulating FSH level above the threshold necessary to support multi‐follicular growth for an entire week (<a href="./references#CD009577-bbs2-0022" title="DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , IJzerman‐BoonPC , FauserBCJM , the ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. ">Devroey 2009</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). As such, a single injection of long‐acting FSH can replace seven daily FSH injections during the first week of COS. </p> </section> <section id="CD009577-sec-0020"> <h3 class="title" id="CD009577-sec-0020">Why it is important to do this review</h3> <p>The development of this new treatment regimen may provide similar or better success rates with fewer injections. It may help to reduce the treatment burden and make the therapy more patient friendly. On the other hand, it could also be more costly. This is an update of a Cochrane review first published in 2012. It considered the evidence from RCTs for the use of long‐acting FSH on pregnancy and safety outcomes. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009577-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009577-sec-0021"></div> <p>To compare the effectiveness of long‐acting FSH versus daily FSH in terms of pregnancy and safety outcomes in women undergoing IVF or ICSI treatment cycles. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009577-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009577-sec-0022"></div> <section id="CD009577-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009577-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). Only trials that were clearly randomised were included. We planned to include cross‐over trials but we did not find any cross‐over trials comparing long‐acting FSH with daily FSH. </p> </section> <section id="CD009577-sec-0025"> <h4 class="title">Types of participants</h4> <p>Subfertile couples with an indication for COS as part of an IVF/ICSI cycle.</p> </section> <section id="CD009577-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Trials comparing long‐acting FSH versus daily FSH were eligible for inclusion. Any dose was included. We included both GnRH antagonist or agonist protocol. </p> </section> <section id="CD009577-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD009577-sec-0028"> <h5 class="title">Primary outcomes</h5> <section id="CD009577-sec-0029"> <h6 class="title">Effectiveness</h6> <p> <ul id="CD009577-list-0001"> <li> <p>Live birth rate per woman randomised, defined as the delivery of one or more living babies after 20 completed weeks of gestation. When there were multiple live births (e.g. twins or triplets), we counted these as one live birth event </p> </li> </ul> </p> </section> <section id="CD009577-sec-0030"> <h6 class="title">Adverse</h6> <p> <ul id="CD009577-list-0002"> <li> <p>OHSS rate per woman randomised</p> </li> </ul> </p> </section> </section> <section id="CD009577-sec-0031"> <h5 class="title">Secondary outcomes</h5> <section id="CD009577-sec-0032"> <h6 class="title">Effectiveness</h6> <p> <ul id="CD009577-list-0003"> <li> <p>Ongoing pregnancy rate per woman randomised, defined as evidence of a gestational sac with fetal heart motion at 12 weeks, confirmed by ultrasound </p> </li> <li> <p>Clinical pregnancy rate per woman randomised, defined as the presence of a gestational sac with or without a fetal heart beat, confirmed by ultrasound </p> </li> </ul> </p> </section> <section id="CD009577-sec-0033"> <h6 class="title">Adverse</h6> <p> <ul id="CD009577-list-0004"> <li> <p>Multiple pregnancy rate per woman randomised, counted as one live birth event</p> </li> <li> <p>Miscarriage rate per woman randomised</p> </li> <li> <p>Any other adverse event per woman randomised (including ectopic pregnancy, congenital malformation, drug side effects and infection) </p> </li> </ul> </p> </section> <section id="CD009577-sec-0034"> <h6 class="title">Process</h6> <p> <ul id="CD009577-list-0005"> <li> <p>Patient satisfaction with the treatment</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD009577-sec-0035"> <h3 class="title">Search methods for identification of studies</h3> <p>We sought all published and unpublished RCTs studying long‐acting FSH versus daily FSH. We used the following search strategy, without language restriction and in consultation with the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Trials Search Co‐ordinator. </p> <section id="CD009577-sec-0036"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases, trial registers and websites using Ovid software: </p> <p> <ul id="CD009577-list-0006"> <li> <p>Cochrane MDSG Specialized Register of Controlled Trials (from inception to June 2015) (<a href="./appendices#CD009577-sec-0172">Appendix 2</a>) </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (from inception to June 2015) (<a href="./appendices#CD009577-sec-0173">Appendix 3</a>) </p> </li> <li> <p>MEDLINE (1950 to June 2015) (<a href="./appendices#CD009577-sec-0174">Appendix 4</a>) </p> </li> <li> <p>EMBASE (from inception to June 2015) (<a href="./appendices#CD009577-sec-0175">Appendix 5</a>) </p> </li> <li> <p>PsycINFO (1982 to June 2015) (<a href="./appendices#CD009577-sec-0176">Appendix 6</a>) </p> </li> <li> <p>CINAHL (from inception to June 2015) (<a href="./appendices#CD009577-sec-0177">Appendix 7</a>) </p> </li> </ul> </p> <p>The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomised trials that appears in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009577-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We combined the EMBASE search with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN). </p> <p>Also we checked the following electronic sources for trials:</p> <p> <ul id="CD009577-list-0007"> <li> <p>Trial registers for ongoing and registered trials: 'Current Controlled Trials' (<a href="http://www.controlled-trials.com/" target="_blank">http://www.controlled‐trials.com/</a>); 'ClinicalTrials.gov', a service of the US National Institutes of Health (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">http://clinicaltrials.gov/ct2/home</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">http://www.who.int/trialsearch/Default.aspx</a>) </p> </li> <li> <p>Citation indexes (<a href="http://scientific.thomson.com/products/sci/" target="_blank">http://scientific.thomson.com/products/sci/</a>) </p> </li> <li> <p>Conference abstracts and other trials in the Web of Science (http://wokinfo.com/) (<a href="./appendices#CD009577-sec-0178">Appendix 8</a>) </p> </li> <li> <p>LILACS database, as a source of trials from the Portuguese and Spanish speaking world (<a href="http://htpp:/regional.bvsalud.org/php/index.php?lang=en" target="_blank">htpp://regional.bvsalud.org/php/index.php?lang=en</a>) (choose 'LILACS' in 'all sources' drop‐down box) </p> </li> <li> <p>PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed/" target="_blank">http://www.ncbi.nlm.nih.gov/pubmed/</a>), the random control filter for PubMed was taken from the searching chapter of the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD009577-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a><i>).</i> </p> </li> <li> <p>OpenGrey database for grey literature from Europe (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu</a>). </p> </li> </ul> </p> </section> <section id="CD009577-sec-0037"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of articles retrieved by the search and contacted experts in the field and manufacturers of long‐acting FSH in order to obtain any additional relevant data. </p> </section> </section> <section id="CD009577-sec-0038"> <h3 class="title" id="CD009577-sec-0038">Data collection and analysis</h3> <p>We conducted data collection and analyses in accordance with the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009577-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <section id="CD009577-sec-0039"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AP, CF) independently scanned the titles and abstracts of articles retrieved by the search and removed those that were very clearly irrelevant. Full texts of all potentially eligible studies were retrieved. Two review authors independently examined the full text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review. We discussed any disagreement or doubt as to whether a study was eligible for inclusion or not with a third review author (JK) and achieved consensus. A list of the excluded studies and the reasons for exclusion are provided in the '<a href="./references#CD009577-sec-0194" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD009577-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>We extracted data from eligible studies using a data extraction form we had designed and pilot‐tested. Where studies had multiple publications, we used the main trial report as the reference and additional details were supplemented from secondary papers. As there were studies with four arms, three dosage arms and one control group, it was necessary to divide the control group by three. If the study did not report the outcomes per dosage subgroup, we divided the intervention group by three. Where this number was even, then we made an arbitrary decision to increase or reduce the number of cases by one in one of the three groups. We corresponded with study investigators in order to resolve any data queries, as required. Two review authors independently extracted the data. A third review author resolved any disagreements. </p> </section> <section id="CD009577-sec-0041"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies using the Cochrane 'Risk of bias' assessment tool, which recommends the explicit reporting of the following domains: </p> <p> <ol id="CD009577-list-0008"> <li> <p>Random sequence generation (selection bias)</p> <ul id="CD009577-list-0009"> <li> <p>Adequate: use of central computer randomisation, independent central randomisation office, on‐site computer from which assignment could only be determined after entering patient data, random number table or serially numbered and sealed opaque envelopes </p> </li> <li> <p>Inadequate: no random sequence generation</p> </li> <li> <p>Unclear: insufficient information about the process of sequence generation</p> </li> </ul> </li> <li> <p>Allocation concealment (selection bias)</p> <ul id="CD009577-list-0010"> <li> <p>Adequate: sequentially numbered and identical drug containers were used</p> </li> <li> <p>Inadequate: use of non‐opaque envelopes or systematic methods (e.g. date of birth, medical record number, day of the week presenting) </p> </li> <li> <p>Unclear: insufficient information about the process of allocation concealment</p> </li> </ul> </li> <li> <p>Blinding of participants, researchers and care providers (performance bias)</p> <ul id="CD009577-list-0011"> <li> <p>Adequate: blinding of the participants, researchers and the care providers, or incomplete or no blinding was used but was not likely to influence outcomes </p> </li> <li> <p>Inadequate: no blinding or incomplete blinding was used and likely to influence the outcomes </p> </li> <li> <p>Unclear: insufficient information about the process of blinding the participants, researchers and care providers </p> </li> </ul> </li> <li> <p>Blinding of the outcome assessor (detection bias)</p> <ul id="CD009577-list-0012"> <li> <p>Adequate: blinding of the researchers or incomplete blinding had no effect on the outcome measurement </p> </li> <li> <p>Inadequate: no blinding of the researchers, or incomplete blinding had influence on the outcomes </p> </li> <li> <p>Unclear: insufficient information about the process of blinding the outcome assessor</p> </li> </ul> </li> <li> <p>Incomplete outcome data (attrition bias)</p> <ul id="CD009577-list-0013"> <li> <p>Adequate: there were no missing data, or reasons for missing data may not influence the outcomes </p> </li> <li> <p>Inadequate: reasons for missing data may influence the outcomes</p> </li> <li> <p>Unclear: insufficient information about the completeness of outcome data</p> </li> </ul> </li> <li> <p>Selective outcome reporting (reporting bias)</p> <ul id="CD009577-list-0014"> <li> <p>Adequate: all pre‐specified outcomes in the protocol have been published, or no protocol available but it was clear all pre‐specified outcomes were reported </p> </li> <li> <p>Inadequate: not all pre‐specified outcomes in the protocol were reported</p> </li> <li> <p>Unclear: insufficient information about the process of outcome reporting</p> </li> </ul> </li> <li> <p>Other potential sources of bias</p> <ul id="CD009577-list-0015"> <li> <p>Adequate: the study was free of other biases</p> </li> <li> <p>Inadequate: other biases were present</p> </li> <li> <p>Unclear: insufficient information about the other sources of bias</p> </li> </ul> </li> </ol> </p> <p>Two review authors assessed these seven domains as at 'low' (adequate), 'high' (inadequate), or 'unclear' risk of bias (unclear). The assessments made by the two review authors were compared and we resolved any disagreements by consensus or by discussion with a third review author. We presented the conclusion in the 'Risk of bias' tables and incorporated these results into the interpretation of review findings by means of sensitivity analyses. </p> </section> <section id="CD009577-sec-0042"> <h4 class="title">Measures of treatment effect</h4> <p>We used the dichotomous data measures and expressed the results in the control and intervention groups of each study as risk ratios (RR) with 95% confidence intervals (CI). </p> </section> <section id="CD009577-sec-0043"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomised. All included studies reported data per woman. We counted multiple live births (e.g. twins or triplets) as one live birth event. </p> </section> <section id="CD009577-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p>In the case of missing data from the included studies, we contacted the original investigators to request the relevant missing data. We did not received the requested data so we made an imputation of individual values for the primary outcomes only. Live births were assumed not to have occurred in participants without a reported outcome. We analysed all data on an intention‐to‐treat (ITT) basis. </p> </section> <section id="CD009577-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a meaningful summary. We used the I² statistic to assess the impact of the heterogeneity on the meta‐analysis. We interpreted the result of the I² statistic as follows: </p> <p> <ul id="CD009577-list-0016"> <li> <p>0% to 40%, might not be important</p> </li> <li> <p>30% to 60%, may represent moderate heterogeneity</p> </li> <li> <p>50% to 90%, may represent substantial heterogeneity</p> </li> <li> <p>75% to 100%, considerable heterogeneity (<a href="./references#CD009577-bbs2-0028" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>) </p> </li> </ul> </p> </section> <section id="CD009577-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched for within trial selective reporting, such as trials failing to report obvious outcomes or reporting them in insufficient detail to allow inclusion. We sought published protocols to look for any pre‐planned outcomes that may not have been reported and compared the outcomes between the protocol and the final published study.<br/> We planned to undertake informal assessment if included studies failed to report the primary outcome of live birth, but all studies reported live birth. </p> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise the potential impact by ensuring a comprehensive search for eligible studies. We were alert for duplication of data. To investigate the potential for publication bias, we planned to use a funnel plot if there were 10 or more studies in an analysis. However, due to the small number of studies per subgroup this was not possible. </p> </section> <section id="CD009577-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses using <a href="./references#CD009577-bbs2-0032" title="The Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014. ">RevMan 2014</a>. We used a fixed‐effect model to combine the data from primary studies. We planned to perform a random‐effects meta‐analysis in the case of substantial heterogeneity, but this was not necessary. </p> </section> <section id="CD009577-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed data in the following subgroups:</p> <p>Dose of long‐acting FSH:</p> <p> <ul id="CD009577-list-0017"> <li> <p>Low (60 to 120 μg)</p> </li> <li> <p>Medium (150 to 180 μg)</p> </li> <li> <p>High (240 μg)</p> </li> </ul> </p> <p>We planned to do subgroup analyses on: women's age; weight; body mass index (BMI); day of starting GnRH antagonist; and poor responders to ovarian stimulation. However, we were unable to perform these subgroup analyses due to insufficient information. </p> </section> <section id="CD009577-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses for the primary outcomes to determine whether the conclusions were robust regarding the eligibility and analysis of studies. We explored whether exclusion of trials with high risk of bias had an impact on the results. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009577-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009577-sec-0050"></div> <section id="CD009577-sec-0051"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD009577-sec-0193" title="">Characteristics of included studies</a>, <a href="./references#CD009577-sec-0194" title="">Characteristics of excluded studies</a>, Characteristics of ongoing studies sections. </p> <section id="CD009577-sec-0052"> <h4 class="title">Results of the search</h4> <p>See: study flow diagram <a href="#CD009577-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD009577-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009577-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The original search was done on 10 October 2011 (for our search strategy see <a href="#CD009577-sec-0022">Methods</a>). Using the search strings stated in <a href="./appendices#CD009577-sec-0172">Appendix 2</a> to <a href="./appendices#CD009577-sec-0178">Appendix 8</a>, we retrieved 107 articles. We also searched LILICS, <i>meta</i> Register of Controlled Trials‐active registers, WHO ICTRP, clinicaltrials.gov, clinicalstudyresults.org, OpenSIGLE and PubMed (MeSH terms used) using the keywords '<i>corifollitropin</i> ', '<i>corifollitropin alfa</i> ', '<i>corifollitropin alpha</i> ', '<i>ORG 36286</i> ', '<i>Elonva</i> ', '<i>FSH‐CTP</i> ', '<i>long‐acting FSH</i> ', '<i>long acting FSH</i> '<i>.</i> We retrieved 76 reports, and identified another three reports by using other methods, such as handsearching. After removal of duplicates, we screened titles and exclued clearly irrelevant articles. We retrieved the remaining studies in full‐text or were conference abstracts, protocols or clinical study results. The reports that did not appear to meet our inclusion criteria were excluded. Five trials met our inclusion criteria, and one study was a duplicate (<a href="./references#CD009577-bbs2-0025" title="FauserBC , MannaertsBM , DevroeyP , LeaderA , BoimeI , BairdDT . Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle‐stimulating activity and reduced injection frequency. Human Reproduction Update2009;15(3):309‐21. ">Fauser 2009</a>). We also found two ongoing trials and one conference abstract with preliminary results (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). For details see the Characteristics of ongoing studies section. </p> <p>On <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> we found the protocols of the four included studies and six protocols of follow‐up studies of the original included studies. We found clinical study reports of all protocols on <a href="http://www.clinicalstudyresults.org" target="_blank">clinicalstudyresults.org</a>. We included four trials and the data of four conference abstracts, six protocols and six reports of clinical study results in our meta‐analyses. Overall, we included four trials. </p> <p>A new search was performed on 08 June 2015. We used the search strings stated in <a href="./appendices#CD009577-sec-0172">Appendix 2</a> to <a href="./appendices#CD009577-sec-0178">Appendix 8</a> and retrieved 120 articles. We also searched LILICS, <i>meta</i> Register of Controlled Trials‐active registers, WHO ICTRP, clinicaltrials.gov, clinicalstudyresults.org, OpenGrey and PubMed (MeSH terms used) using the keywords '<i>corifollitropin</i> ', '<i>corifollitropin alfa', 'corifollitropin alpha', 'ORG 36286', 'Elonva', 'FSH‐CTP', 'long‐acting FSH', 'long acting FSH'.</i> This search retrieved three additional records. After screening titles and full‐text articles we found two trails meeting our inclusion criteria. Two studies, which were ongoing at the time of the original search, are included in our updated meta‐analysis (<a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>; <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). We also found the study protocol of both studies and one conference abstract with follow‐up data. We also included an erratum of <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>. </p> </section> <section id="CD009577-sec-0053"> <h4 class="title">Included studies</h4> <section id="CD009577-sec-0054"> <h5 class="title">Study design and setting</h5> <p>We included six RCTs in the review. Five were multi‐centre trials, conducted in Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Norway, Poland, Spain, Sweden, The Netherlands, UK), North America (Canada, USA) and Asia (Korea, Taiwan). One one‐centre clinical trial was conducted in Greece (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). We included two four‐arm trials (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>) and four two‐arm trials (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>; <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). As there were studies with four arms, three dosage arms and one control group, it was necessary to divide the control group by three. If the study did not report live births per dosage subgroup we divided the intervention group by three. Where this number was even, then we made an arbitrary decision to increase or reduce the number of cases by one in one of the three groups. </p> </section> <section id="CD009577-sec-0055"> <h5 class="title">Participants</h5> <p>A total of 3753 women participated in the included studies, 2054 women in the intervention groups and 1699 women in the control groups. The age of the included participants ranged from 18 to 42 years, and the range of BMI was 17 to 32 kg/m². </p> <p>The inclusion criteria differed slightly between the studies regarding age, BMI and weight. <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> included women with a body weight ≤ 60 kg and BMI of 18 to 32 kg/m². <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> included women weighing &gt; 60 kg and ≤ 90 kg with BMI 18 to 32 kg/m². The three other studies included women weighing between 50 to 90 kg and BMI 18.0 to 32.0 kg/m² (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> included women weighing between 60 to 90 kg and with a BMI 18.0 to 32.0 kg/m². There were differences for the inclusion and exclusion criteria between the protocols and the published articles. <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a> reported an inclusion age range of 20 to 39 years in the article while they stated 18 to 39 years in the protocol. <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> reported none of the exclusion criteria as stated in the protocol. All studies excluded poor responders, patients with a history of OHSS or polycystic ovary syndrome (PCOS) (hyper‐responders) and women with a cause for subfertility. </p> <p>We have presented a summary in <a href="#CD009577-tbl-0002">Table 1</a>; for details see the <a href="./references#CD009577-sec-0193" title="">Characteristics of included studies</a> tables. </p> <div class="table" id="CD009577-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant BMI (kg/m²)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant weight (kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Start GnRH antagonist </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of embryos transferred</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Poor responders</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leading follicle ≥ 14 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 60 and ≤ 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 to 39</p> <p>Protocol: 18 to 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 to 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 to 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both agonist and antagonist protocol used, day not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009577-sec-0056"> <h5 class="title">Interventions</h5> <p>Five included studies compared long‐acting FSH with daily FSH and followed by a GnRH antagonist protocol. <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> used both GnRH agonist and antagonist protocol. The studies varied in initial dose of long‐acting FSH administered: 454 women received a low dose (60 to 120 μg) (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>), 1575 women received a medium dose (150 to 180 μg) (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>; <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>) and 25 women received a high dose (240 μg) (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>). All studies used daily FSH for the control group: three studies used 150 IU daily FSH (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>) and <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> used 200 IU daily FSH. <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> used daily FSH 300 IU. <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> and <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> used a bodyweight adjusted dose of long‐acting and daily FSH. </p> <p>GnRH antagonist was administered subcutaneously. <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> started on the day the leading follicle reached 14 mm. Four other studies started on day 5. <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> did not state day of administration (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). See <a href="#CD009577-tbl-0002">Table 1</a>. </p> <p>The number of transferred embryos varied from one, two or three embryos; see <a href="#CD009577-tbl-0002">Table 1</a>. </p> </section> <section id="CD009577-sec-0057"> <h5 class="title">Outcomes</h5> <section id="CD009577-sec-0058"> <h6 class="title">Primary outcomes</h6> <section id="CD009577-sec-0059"> <p><b>Effectiveness</b></p> <p>Five clinical trial reports reported live birth rate, with additional data obtained by follow‐up studies of the original trial. </p> </section> <section id="CD009577-sec-0060"> <p><b>Adverse</b></p> <p>All six include studies reported OHSS. We reported the total number of OHSS cases, including mild, moderate and severe cases. </p> </section> </section> <section id="CD009577-sec-0061"> <h6 class="title">Secondary outcomes</h6> <section id="CD009577-sec-0062"> <p><b>Effectiveness</b></p> <p>Five studies reported clinical pregnancy rate. These five studies stated both the number of clinical pregnancies (defined as presence of gestational sac confirmed by ultrasound) and the number of ongoing pregnancies (defined as evidence of a gestational sac and heartbeat at 12 weeks confirmed by ultrasound). We reported both outcomes per women randomised. If results after both fresh and frozen embryo transfer were given, we reported the ongoing pregnancy rate after fresh embryo transfer. </p> </section> <section id="CD009577-sec-0063"> <p><b>Adverse</b></p> <p>Five studies reported multiple pregnancy rate. <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> reported three sets of twins in the intervention groups; we assumed that one twin pregnancy occurred in each intervention group. Three studies reported miscarriage rate (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). Three studies reported ectopic pregnancy rate as an adverse event (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>). Three studies reported congenital malformations (major and minor) per live born infant (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). Major malformations were defined as any congenital malformation that causes functional impairment or requires surgical correction. Minor malformations were defined as any congenital malformation not classified as major. </p> <p>We had insufficient data to report any other adverse events.</p> </section> <section id="CD009577-sec-0064"> <p><b>Process</b></p> <p>None of the included studies reported patient satisfaction with the treatment.</p> </section> </section> </section> </section> <section id="CD009577-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies from the review. Eleven studies were not RCTs (<a href="./references#CD009577-bbs2-0008" title="CroxtallJD , McKeageK . Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs2011;25(4):243‐54. ">Croxtall 2011</a>; <a href="./references#CD009577-bbs2-0009" title="deLartigueJ . Corifollitropin alfa: a new option to treat female infertility. Drugs of Today2011;47(8):583‐90. ">de Lartigue 2011</a>; <a href="./references#CD009577-bbs2-0010" title="FatemiHM , OberyéJ , Popovic‐TodorovicB , WitjesH , MannaertsB , DevroeyP . Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertility and Sterility2010;94(5):1922‐4. ">Fatemi 2010</a>; <a href="./references#CD009577-bbs2-0012" title="LedgerW , ZandvlietA , MannaertsB . On behalf on the ENGAGE/ENSURE investigators: Two doses of corifollitropin alfa allow for similar exposure and ovarian response in patients weighing ≤60 kg and &gt;60 kg. Molecular Human Reproduction2009;24(Suppl 1):i114. ">Ledger 2009</a>; <a href="./references#CD009577-bbs2-0013" title="LoutradisD , VlismasA , DrakakisP . Corifollitropin alfa: a novel long‐acting recombinant follicle‐stimulating hormone agonist for controlled ovarian stimulation. Women's Health2010;6(5):655‐64. ">Loutradis 2010</a>; <a href="./references#CD009577-bbs2-0014" title="Mahmoud YoussefMA , vanWelyM , AboulfoutouhI , El‐KhyatW , van derVeenF , Al‐InanyH . Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta‐analysis. Fertility and Sterility2012;97(4):876‐85. ">Mahmoud Youssef 2012</a>; <a href="./references#CD009577-bbs2-0015" title="NormanRJ , Zegers‐HochschildF , SalleBS , ElbersJ , HeijnenE , Marintcheva‐PetrovaM , et al. Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity. Human Reproduction2011;26(8):2200‐8. ">Norman 2011</a>; <a href="./references#CD009577-bbs2-0016" title="PradosN , PellicerA , Fernandez‐SanchezM . Corifollitropin alfa: A new recombinant FSH gonadotropin analogue. Expert Review of Obstetrics and Gynecology2011;6(4):395‐402. ">Prados 2011</a>; <a href="./references#CD009577-bbs2-0017" title="RombautsL , TalmorA . Corifollitropin alfa for female infertility. Expert Opinion on Biological Therapy2012;12(1):107‐12. ">Rombauts 2012</a>; <a href="./references#CD009577-bbs2-0018" title="SeyhanA , BarisA . The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. International Journal of Women's Health2011;3:243‐55. ">Seyhan 2011</a>; <a href="./references#CD009577-bbs2-0019" title="TalmorA , McLachlanV , OsianlisT , SorbyKL , LutjenP . Is longer better? The long and short of it ‐ a matched case control study of long and short acting follicle stimulating hormone. Fertility and Sterility2013;100(Supplement 3):S17. ">Talmor 2013</a>). We excluded <a href="./references#CD009577-bbs2-0007" title="BalenAH , MuldersAG , FauserBC , SchootBC , RenierMA , DevroeyP , et al. Pharmacodynamics of a single low dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. Journal of Clinical Endocrinology and Metabolism2004;89(12):6297‐304. ">Balen 2004</a> because the included women did not undergo IVF or ICSI after the stimulation. <a href="./references#CD009577-bbs2-0011" title="LeaderA , DevroeyP , WitjesH , GordonK . Corifollitropin alfa or rFSH treatment flexibility options for controlled ovarian stimulation: a post hoc analysis of the Engage trial. Reproductive Biology and Endocrinology2013;11:52. ">Leader 2013</a> did not report outcomes of interest to this review. </p> <p>See the <a href="./references#CD009577-sec-0194" title="">Characteristics of excluded studies</a> table for details. </p> </section> </section> <section id="CD009577-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for each included trial and recorded these results in the 'Risk of bias' table (see <a href="./references#CD009577-sec-0193" title="">Characteristics of included studies</a>). We summarised our findings in the 'Risk of bias' graph (<a href="#CD009577-fig-0006">Figure 6</a>) and 'Risk of bias' summary (<a href="#CD009577-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD009577-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009577-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009577-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009577-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>We contacted the study authors for supplementary information. Five studies had the same contact author; we did not receive any of the requested data (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). One contact author provided us with the requested data (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). </p> <section id="CD009577-sec-0067"> <h4 class="title">Allocation</h4> <section id="CD009577-sec-0068"> <h5 class="title">Random sequence generation</h5> <p>All six included studies were randomised. We judged four studies at low risk of selection bias. Three of four used randomly permutated blocks with an undisclosed fixed block size (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> randomised by telephone to a person totally irrelevant of the unit, by answering to random numbers which had been chosen before by the couple and provider. Thus we judged this trial at low risk of bias. We judged two studies at unclear risk of selection bias related to random sequence generation because the study authors did not report the method of randomisation used (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). </p> </section> <section id="CD009577-sec-0069"> <h5 class="title">Allocation concealment</h5> <p>Three studies concealed allocation by using central remote allocation and we judged these studies to be at low risk of bias (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). Two studies did not describe the method of allocation concealment and we judged these to be unclear risk of bias (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). </p> </section> </section> <section id="CD009577-sec-0070"> <h4 class="title">Blinding</h4> <section id="CD009577-sec-0071"> <h5 class="title">Blinding of participants and personnel</h5> <p>All six studies reported their method of blinding. Two studies were open‐label trials (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>) and were judged at high risk of bias. One study was not blinded, and we judged this study at high risk of bias (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). Three studies were double‐blind and described use of a double‐dummy placebo and were thus we deemed them to be at low risk of performance bias (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). </p> </section> <section id="CD009577-sec-0072"> <h5 class="title">Blinding of outcome assessment</h5> <p><a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> blinded the outcome assessor, and we judged this trial at low risk of bias. Two studies did not report the blinding of outcome assessors and we judged them to be at unclear risk of bias (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>). One study was not blinded (<a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>). The other two studies were open‐label trials and for this reason we judged them to be at high risk of detection bias (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). </p> </section> </section> <section id="CD009577-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Two studies were at high risk of attrition bias. <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> did not report reasons for all withdrawals. They reported in their protocol six participants treated with long‐acting FSH during this trial; these treated participants were not analysed in their publication. We decided to analyse 105 participants in our meta‐analysis (99 participants analysed in the published paper and six participants treated as stated in the protocol). We found <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> to be at high risk of bias because the trial had a high unexplained drop‐out rate. Three studies were judged to be at low risk of bias because they reported all numbers and reasons for withdrawals (<a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>; <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a>). We used preliminary data of <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a>, and as no dropouts were reported, risk of bias was unclear. </p> </section> <section id="CD009577-sec-0074"> <h4 class="title">Selective reporting</h4> <p>We were able to obtain the protocols for all included studies and all pre‐specified outcomes were reported in either the published articles or unpublished data on clinical study reports (<a href="http://clinicalstudyresults.gov" target="_blank">clinicalstudyresults.gov</a>). We judged five studies to be at low risk of reporting bias. We judged <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> at high risk of bias because they didn't report the outcomes as stated in the original study protocol. </p> </section> <section id="CD009577-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>We judged five trials at unclear risk of other bias because they were funded by Schering‐Plough (NV Organon). <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> also received fees and grants from Ferring, Bessins, Serono, Merck Serono, IBSA, Wyeth, Schering, Ardana, Andromed, Pantrhei Bioscience and Preglem. The protocol of <a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> stated "The investigator agreed not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agreed to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report(s) any results of the trial", so we judged it to be at high risk of bias. <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> did not received any pharmaceutical fees or grants, and we judged it at low risk of bias. </p> </section> </section> <section id="CD009577-sec-0076"> <h3 class="title" id="CD009577-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD009577-tbl-0001"><b>Summary of findings for the main comparison</b> Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</a> </p> <p>We did not conduct all the subgroup analyses as stated in our protocol. We had insufficient data to conduct the analyses (see <a href="#CD009577-tbl-0002">Table 1</a>). We compared long‐acting FSH (all doses) versus daily FSH with the following subgroups: </p> <p>Dose of long‐acting FSH:</p> <p> <ul id="CD009577-list-0018"> <li> <p>Low (60 to 120 μg)</p> </li> <li> <p>Medium (150 to 180 μg)</p> </li> <li> <p>High (240 μg)</p> </li> </ul> </p> <section id="CD009577-sec-0077"> <h4 class="title">Primary outcomes</h4> <section id="CD009577-sec-0078"> <h5 class="title">1.1 Live birth rate</h5> <p>Five trials reported the numbers of live births. There was no evidence of a difference between long‐acting FSH versus daily FSH. Moderate heterogeneity was detected (RR 0.95, 95% CI 0.84 to 1.07; five studies, 2363 participants; I² statistic = 44%). </p> <section id="CD009577-sec-0079"> <h6 class="title">1.1.1 Low dose</h6> <p>There was evidence of a reduced live birth rate in women who received lower doses (60 to 120 μg) of long‐acting FSH compared to daily FSH (RR 0.70, 95% CI 0.52 to 0.93; 645 participants, three studies; I² statistic = 0%; <i>moderate quality evidence</i>). </p> </section> <section id="CD009577-sec-0080"> <h6 class="title">1.1.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 1.03, 95% CI 0.90 to 1.18; 1685 participants, four studies; I² statistic = 6%, <i>moderate quality evidence</i>). </p> </section> <section id="CD009577-sec-0081"> <h6 class="title">1.1.3 High dose</h6> <p>There was no evidence of a difference between the groups (RR 0.43, 95% CI 0.12 to 1.52; 33 participants, one study; <i>very low quality evidence).</i> </p> <p>See <a href="./references#CD009577-fig-0010" title="">Analysis 1.1</a> and <a href="#CD009577-fig-0008">Figure 8</a> for details. </p> <div class="figure" id="CD009577-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.1 Live birth rate." data-id="CD009577-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.1 Live birth rate. </p> </div> </div> </div> </section> </section> <section id="CD009577-sec-0082"> <h5 class="title">1.2 Ovarian hyperstimulation syndrome (OHSS)</h5> <p>All six trials reported this primary adverse event. There was no evidence of a difference between the groups for this adverse outcome (RR 1.00, 95% CI 0.74 to 1.37; 3753 participants, six studies; I² statistic = 0%). </p> <section id="CD009577-sec-0083"> <h6 class="title">1.2.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 1.22, 95% CI 0.56 to 2.66; 645 participants, three studies; I² statistic = 0%; <i>moderate quality evidence</i>). </p> </section> <section id="CD009577-sec-0084"> <h6 class="title">1.2.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 0.96, 95% CI 0.68 to 1.35; 3075 participants, five studies; I² statistic = 9%; <i>low quality evidence</i>). </p> </section> <section id="CD009577-sec-0085"> <h6 class="title">1.2.3 High dose</h6> <p>There was no evidence of a difference between the groups (RR 1.73, 95% CI 0.09 to 32.75; 33 participants, one study; <i>low quality evidence</i>). </p> <p>See <a href="./references#CD009577-fig-0011" title="">Analysis 1.2</a> and <a href="#CD009577-fig-0009">Figure 9</a> for details. </p> <div class="figure" id="CD009577-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.2 OHSS." data-id="CD009577-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.2 OHSS. </p> </div> </div> </div> </section> </section> </section> <section id="CD009577-sec-0086"> <h4 class="title">Secondary outcomes</h4> <section id="CD009577-sec-0087"> <h5 class="title">1.3 Ongoing pregnancy rate</h5> <p>All six included studies reported ongoing pregnancy rate. There was no evidence of a difference between the groups (RR 0.95, 95% CI 0.86 to 1.04; 3753 participants, six studies; I² statistic = 19%). </p> <section id="CD009577-sec-0088"> <h6 class="title">1.3.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.78, 95% CI 0.59 to 1.04; 645 participants, three studies; I² statistic = 13%). </p> </section> <section id="CD009577-sec-0089"> <h6 class="title">1.3.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 0.98, 95% CI 0.88 to 1.09; 3075 participants, five studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0090"> <h6 class="title">1.3.3 High dose</h6> <p>There was no evidence of a difference between the groups (RR 0.48, 95% CI 0.18 to 1.28; 33 participants, one study). </p> <p>See <a href="./references#CD009577-fig-0012" title="">Analysis 1.3</a> for details. </p> </section> </section> <section id="CD009577-sec-0091"> <h5 class="title">1.4 Clinical pregnancy rate</h5> <p>Five trials reported clinical pregnancy rate. There was no evidence of a difference between the groups (RR 0.94, 95% CI 0.85 to 1.03; 3648 participants, five studies; I² statistic = 14%). </p> <section id="CD009577-sec-0092"> <h6 class="title">1.4.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.78, 95% CI 0.59 to 1.04; 610 participants, two studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0093"> <h6 class="title">1.4.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 0.96, 95% CI 0.87 to 1.07; 3038 participants, four studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0094"> <h6 class="title">1.4.3 High dose</h6> <p>We were unable to conduct high dose subgroup analysis as no data were available.</p> <p>See <a href="./references#CD009577-fig-0013" title="">Analysis 1.4</a> for details. </p> </section> </section> <section id="CD009577-sec-0095"> <h5 class="title">1.5 Multiple pregnancy rate</h5> <p>Five studies reported the adverse event multiple pregnancy rate. There was no evidence of a difference between the groups (RR 1.17, 95% CI 0.89 to 1.54; 2363 participants = 2363, five studies; I² statistic = 0%). </p> <section id="CD009577-sec-0096"> <h6 class="title">1.5.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 1.02, 95% CI 0.52 to 2.00; 645 participants, three studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0097"> <h6 class="title">1.5.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 1.21, 95% CI 0.90 to 1.63; 1685 participants, four studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0098"> <h6 class="title">1.5.3 High dose</h6> <p>There was no evidence of a difference between the groups (RR 1.04, 95% CI 0.05 to 23.27; 33 participants, one study). </p> <p>See <a href="./references#CD009577-fig-0014" title="">Analysis 1.5</a> for details. </p> </section> </section> <section id="CD009577-sec-0099"> <h5 class="title">1.6 Miscarriage rate</h5> <p>Three studies reported the adverse event of miscarriage rate. There was no evidence of a difference between the groups (RR 1.19, 95% CI 0.74 to 1.92; 1933 participants, three studies; I² statistic = 0%). </p> <section id="CD009577-sec-0100"> <h6 class="title">1.6.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 1.19, 95% CI 0.38 to 3.73; 396 participants, one study). </p> </section> <section id="CD009577-sec-0101"> <h6 class="title">1.6.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 1.19, 95% CI 0.71 to 2.01; 1537 participants, two studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0102"> <h6 class="title">1.6.3 High dose</h6> <p>No data were available to conduct high dose subgroup analysis.</p> <p>See <a href="./references#CD009577-fig-0015" title="">Analysis 1.6</a> for details. </p> </section> </section> <section id="CD009577-sec-0103"> <h5 class="title">1.7 Ectopic pregnancy rate</h5> <p>Three studies reported the adverse event ectopic pregnancy rate. There was no evidence of a difference between the groups(RR 0.86, 95% CI 0.42 to 1.75; 2004 participants, three studies; I² statistic = 0%). </p> <section id="CD009577-sec-0104"> <h6 class="title">1.7.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.97, 95% CI 0.32 to 2.91; 429 participants, two studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0105"> <h6 class="title">1.7.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 0.79, 95% CI 0.31 to 2.02; 1542 participants, two studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0106"> <h6 class="title">1.7.3 High dose</h6> <p>There were no events in either the intervention group or the control group.</p> <p>See <a href="./references#CD009577-fig-0016" title="">Analysis 1.7</a> for details. </p> </section> </section> <section id="CD009577-sec-0107"> <h5 class="title">1.8 Congenital malformation rate</h5> <p>Three studies reported the adverse event congenital malformation rate. There was no evidence of a difference between the groups. We detected moderate heterogeneity (RR 0.96, 95% CI 0.74 to 1.23; 1173 foetuses, three studies; I² statistic = 44%). </p> <section id="CD009577-sec-0108"> <h6 class="title">1.8.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.41, 95% CI 0.16 to 1.07; 135 foetuses, one study; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0109"> <h6 class="title">1.8.2 Medium dose</h6> <p>There was no evidence of a difference between the groups (RR 1.03, 95% CI 0.79 to 1.33; 1038 foetuses, two studies; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0110"> <h6 class="title">1.8.3 High dose</h6> <p>We were unable to conduct high dose subgroup analysis as no data were available.</p> <p>See <a href="./references#CD009577-fig-0017" title="">Analysis 1.8</a> for details. </p> </section> </section> <section id="CD009577-sec-0111"> <h5 class="title">1.9 Major congenital malformation rate</h5> <p>Three studies reported the adverse event major congenital malformation rate. There was no evidence of a difference between the groups (RR 0.93, 95% CI 0.55 to 1.57; 1173 foetuses, three studies; I² statistic = 0%). </p> <section id="CD009577-sec-0112"> <h6 class="title">1.9.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.69, 95% CI 0.14 to 3.28; 135 foetuses, one study; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0113"> <h6 class="title">1.9.2 Medium dose</h6> <p>There was no evidence of a difference between the groups and moderate heterogeneity was detected (RR 0.96, 95% CI 0.55 to 1.69; 1038 foetuses, two studies; I² statistic = 32%). </p> </section> <section id="CD009577-sec-0114"> <h6 class="title">1.9.3 High dose</h6> <p>No data were available to conduct high dose subgroup analysis.</p> <p>See <a href="./references#CD009577-fig-0018" title="">Analysis 1.9</a> for details. </p> </section> </section> <section id="CD009577-sec-0115"> <h5 class="title">1.10 Minor congenital malformation rate</h5> <p>Three studies reported the adverse event of minor congenital malformation rate. There was no evidence of a difference between the groups and we detected substantial heterogeneity (RR 0.97, 95% CI 0.72 to 1.30; 1173 foetuses, three studies; I² statistic = 62%). We did not perform a sensitivity analysis as the three included studies did not have a high risk of bias. </p> <section id="CD009577-sec-0116"> <h6 class="title">1.10.1 Low dose</h6> <p>There was no evidence of a difference between the groups (RR 0.29, 95% CI 0.08 to 1.09; 135 foetuses, one study; I² statistic = 0%). </p> </section> <section id="CD009577-sec-0117"> <h6 class="title">1.10.2 Medium dose</h6> <p>There was no evidence of a difference between the groups and we detected moderate heterogeneity (RR 1.05, 95% CI 0.77 to 1.43; 1038 foetuses, two studies; I² statistic = 46%). </p> </section> <section id="CD009577-sec-0118"> <h6 class="title">1.10.3 High dose</h6> <p>No data were available to conduct high dose subgroup analysis.</p> <p>See <a href="./references#CD009577-fig-0019" title="">Analysis 1.10</a> for details. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009577-sec-0119" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009577-sec-0119"></div> <section id="CD009577-sec-0120"> <h3 class="title" id="CD009577-sec-0120">Summary of main results</h3> <p>This Cochrane Review evaluated the effectiveness of long‐acting FSH versus daily FSH on pregnancy and safety outcomes in women undergoing IVF or ICSI treatment cycles. There was evidence of a reduced live birth rate in women who received lower doses (60 to 120 μg) of long‐acting FSH compared to daily FSH but no evidence of difference in effect on live birth rate in women receiving a medium dose (150 to 180 μg) of long‐acting FSH compared to daily FSH. Only one small study used a high dose (240 μg) of long‐acting FSH and at present this is of no clinical value. The meta‐analyses of effectiveness for the outcomes of clinical pregnancy and ongoing pregnancy did not show evidence of a difference of effect between long‐acting and daily FSH. Similarly, there was no evidence of a difference in adverse events for OHSS rate, multiple pregnancy rate, miscarriage rate, ectopic pregnancy rate and congenital malformation (major or minor) between long‐acting FSH and daily FSH. We can conclude that medium dose (150 to 180 μg) long‐acting FSH is a safe treatment option, with no difference in benefits or harm. </p> <p>See Summary of findings table 1 for a complete overview.</p> </section> <section id="CD009577-sec-0121"> <h3 class="title" id="CD009577-sec-0121">Overall completeness and applicability of evidence</h3> <p>We included all RCTs comparing long‐acting FSH with daily FSH in this Cochrane Review. All six included trials reported on the primary outcomes of live birth rate and OHSS rate. Women at high risk of OHSS (hyper‐responders) were excluded; this provides an explanation for the poor effect of long‐acting FSH on the OHSS rate and the low number of OHSS cases in both treatment groups. Also, all included trials excluded poor responders. For this reason, trials did not provide outcome data on the use of long‐acting FSH in poor responders. </p> <p>All studies excluded women with an identified cause of subfertility. Therefore, our meta‐analyses were based on women with unexplained subfertility. Our outcomes do not apply to long‐acting FSH in women with a cause of subfertility. </p> </section> <section id="CD009577-sec-0122"> <h3 class="title" id="CD009577-sec-0122">Quality of the evidence</h3> <p>We included six studies with a total of 3753 participants in our meta‐analyses. The number of participants in each study varied between 28 and 1509. We included both two‐arm (one intervention and one control group) and four‐arm (three intervention groups and one control group) studies. All studies reported their outcomes per woman. Only one study performed an ITT analysis but we had sufficient data to perform ITT analyses. We found differences between the inclusion and exclusion criteria as stated in the protocol and those published in the article (see <a href="./references#CD009577-sec-0193" title="">Characteristics of included studies</a> for details). These differences were minor and did not tend to be relevant. The quality of the evidence for each comparison ranged from very low to moderate. The main limitations in the evidence were risk of attrition bias and imprecision. </p> <p>The included studies differed in the dose of long‐acting FSH. <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> and <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> used a dose adjusted for participant body weight. <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> only included women with a body weight above 60 kg and so they used a medium dose of long‐acting FSH. <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> recruited women weighing less than 60 kg and used a low dose of long‐acting FSH for these women. Both <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> and <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a> also used a low dose but they included women weighing 50 to 90 kg. This may influence the overall effect in the low dose, long‐acting FSH subgroup in favour of long‐acting FSH. </p> <p>Only one trial, <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>, studied a high dose of long‐acting FSH and this treatment subgroup contained only 25 participants. This information is insufficient to make accurate conclusions about the treatment with high dose long‐acting FSH. </p> <p>No studies reported patient satisfaction for long‐acting FSH versus daily FSH treatment so we are unable to determine if long‐acting FSH treatment is more patient friendly than daily FSH. </p> <p>Five included trials were sponsored by the same pharmaceutical company and have the same contact author. This may have introduced a bias in favour of long‐acting FSH treatment. </p> <p>Two studies, <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> and <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>, did not blind the participants, personnel and outcome assessors and this caused a high risk of bias. <a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> blinded only participants. Two studies did not report all the reasons for withdrawals (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>) and <a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> did not report six treated participants in their published article, constituting a high risk of bias. We detected some moderate heterogeneity between the studies and subgroups. This can be explained by differences between the inclusion and exclusion criteria for participants, participant characteristics and the small differences between the treatment after the first seven days of COS. The one analysis with substantial heterogeneity did not include studies with a high risk of bias and as a result no sensitivity analysis could be performed. </p> </section> <section id="CD009577-sec-0123"> <h3 class="title" id="CD009577-sec-0123">Potential biases in the review process</h3> <p>We stated in our protocol (<a href="./references#CD009577-bbs2-0036" title="PouwerAW , FarquharC , KremerJA . Long‐acting FSH versus daily FSH for women undergoing assisted reproduction. Cochrane Database of Systematic Reviews2012, Issue 1. [DOI: 10.1002/14651858.CD009577] ">Pouwer 2012a</a>) that we would perform different subgroup analyses. Due to insufficient data, we performed only the subgroup analysis for dose of long‐acting FSH. We included a small number of studies and for this reason we did not construct a funnel plot. Therefore, we were unable to estimate the existence of publication or other reporting biases. </p> <p><a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> published a conference abstract with preliminary results. We wrote to the study authors and received additional data. We included this data in our meta‐analyses, and this may have introduced bias. </p> <p>The method we adopted to deal with data from four‐arm studies (discussed in detail in <a href="#CD009577-sec-0053">Included studies</a>) may have introduced bias. </p> <p>Two review authors (AWP and CF) extracted all data. AWP compared the extracted data and discussed disagreements and doubts with CF. AWP entered the data into <a href="./references#CD009577-bbs2-0032" title="The Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, the Cochrane Collaboration, 2014. ">RevMan 2014</a> and updated the review. These methods may have introduced bias. </p> </section> <section id="CD009577-sec-0124"> <h3 class="title" id="CD009577-sec-0124">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in agreement with all previous reviews (<a href="./references#CD009577-bbs2-0008" title="CroxtallJD , McKeageK . Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs2011;25(4):243‐54. ">Croxtall 2011</a>; <a href="./references#CD009577-bbs2-0018" title="SeyhanA , BarisA . The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. International Journal of Women's Health2011;3:243‐55. ">Seyhan 2011</a>; <a href="./references#CD009577-bbs2-0014" title="Mahmoud YoussefMA , vanWelyM , AboulfoutouhI , El‐KhyatW , van derVeenF , Al‐InanyH . Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta‐analysis. Fertility and Sterility2012;97(4):876‐85. ">Mahmoud Youssef 2012</a>). </p> <p><a href="./references#CD009577-bbs2-0018" title="SeyhanA , BarisA . The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. International Journal of Women's Health2011;3:243‐55. ">Seyhan 2011</a> included four RCTs (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>) and one uncontrolled clinical trial. There was no evidence of a difference between the groups in ongoing pregnancy rate (two RCTs; OR 0.95; 95% CI 0.79 to 1.15) for long‐acting versus daily FSH. Adverse events and OHSS rate seemed to be similar (OR not published). </p> <p><a href="./references#CD009577-bbs2-0014" title="Mahmoud YoussefMA , vanWelyM , AboulfoutouhI , El‐KhyatW , van derVeenF , Al‐InanyH . Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta‐analysis. Fertility and Sterility2012;97(4):876‐85. ">Mahmoud Youssef 2012</a> included four RCTs (<a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a>; <a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>; <a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a>). There was no evidence of a difference between the groups in ongoing pregnancy rate (two RCTs; OR 0.95, 95% CI 0.79 to 1.15) for long‐acting versus daily FSH. There is evidence of increased number of follicles using long‐acting FSH (four RCTs, weighted mean difference (WMD) 1.99, 95% CI 1.02 to 2.97; P = 0.11). There was no evidence of a difference between the groups in risk of OHSS (four RCTs; OR 1.27, 95% CI 0.72 to 2.22). </p> <p><a href="./references#CD009577-bbs2-0008" title="CroxtallJD , McKeageK . Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction. BioDrugs2011;25(4):243‐54. ">Croxtall 2011</a> included two RCTs (<a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a>; <a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a>). There was no evidence of a difference between the groups in ongoing pregnancy rate (OR not published). The risk of OHSS in the long‐acting FSH group was 7% versus 6.1% for daily FSH (OR not published). </p> <p>In large pooled analyses of clinical trials, the incidence of OHSS in both the corifollitropin alfa and rFSH treatment arms was consistent with that expected in the relatively young patient population. Furthermore, there were no clinically relevant differences in pregnancy complications and the incidence of infant adverse events between treatment arms. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009577-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH antagonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH antagonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH agonist protocol (Source:de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with daily FSH in a GnRH agonist protocol (Source:<a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH antagonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH antagonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH agonist protocol (Source: de Greef 2010). Copyright © 2010 Wiley: reproduced with permission." data-id="CD009577-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Schematic representation of therapeutic interventions during ovarian stimulation with long‐acting FSH (Corifollitropin alfa) in a GnRH agonist protocol (Source: <a href="./references#CD009577-bbs2-0021" title="deGreefR , ZandvlietAS , deHaanAFJ , Ijzerman‐BoonPCI , Marintcheva‐PetrovaM , MannaertsBMJL . Dose selection of corifollitropin alfa by modeling and simulation in controlled ovarian stimulation. Clinical Pharmacology and Therapeutics2010;88(1):79‐87. ">de Greef 2010</a>). Copyright © 2010 Wiley: reproduced with permission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009577-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009577-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009577-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.1 Live birth rate." data-id="CD009577-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.1 Live birth rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.2 OHSS." data-id="CD009577-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Long‐acting FSH (all doses) versus daily FSH, outcome: 1.2 OHSS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 1 Live birth rate." data-id="CD009577-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 1 Live birth rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 2 OHSS." data-id="CD009577-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 2 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 3 Ongoing pregnancy rate." data-id="CD009577-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 3 Ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 4 Clinical pregnancy rate." data-id="CD009577-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 4 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 5 Multiple pregnancy rate." data-id="CD009577-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 5 Multiple pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 6 Miscarriage rate." data-id="CD009577-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 6 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 7 Ectopic pregnancy rate." data-id="CD009577-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 7 Ectopic pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 8 Congenital malformation rate." data-id="CD009577-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 8 Congenital malformation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 9 Major congenital malformation rate." data-id="CD009577-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 9 Major congenital malformation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009577-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/urn:x-wiley:14651858:media:CD009577:CD009577-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_t/tCD009577-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 10 Minor congenital malformation rate." data-id="CD009577-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Long‐acting FSH (all doses) versus daily FSH, Outcome 10 Minor congenital malformation rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/media/CDSR/CD009577/image_n/nCD009577-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009577-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient:</b> Women undergoing assisted reproduction </p> <p><b>Settings:</b> clinic<br/> <b>Intervention:</b> Long‐acting FSH (all doses) </p> <p><b>Control:</b> daily FSH </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Daily FSH</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Long‐acting FSH (all doses) </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ Low dose (60 to 120 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>352 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>246 per 1000</b> <br/> (183 to 327) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.7</b> <br/> (0.52 to 0.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ Medium dose (150 to 180 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>255 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> <br/> (229 to 301) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.9 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1685<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Live birth rate ‐ High dose (240 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>161 per 1000</b> <br/> (45 to 570) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> <br/> (0.12 to 1.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ Low dose (60 to 120 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>57 per 1000</b> <br/> (26 to 125) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/> (0.56 to 2.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>645<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ Medium dose (150 to 180 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> <br/> (43 to 85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.96</b> <br/> (0.68 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3075<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OHSS ‐ High dose (240 μg)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.73</b> <br/> (0.09 to 32.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>very low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for imprecision, due to low event rate<br/> <sup>2</sup> Downgraded one level as two studies (including the largest study) at high risk of attrition bias<br/> <sup>3</sup> Downgraded two levels for imprecision due to very low event rate and downgraded a further level for high risk of attrition bias </p> <p><sup>4</sup> Downgraded for imprecision as confidence intervals compatible with clinically meaningful benefit in either arm or with no effect </p> <p><sup>5</sup> Downgraded for imprecision as confidence intervals compatible with clinically meaningful benefit in either arm or with no effect, and downgraded a further level for high risk of attrition bias in two studies </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Long‐acting FSH (all doses) versus daily FSH for women undergoing assisted reproduction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009577-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant BMI (kg/m²)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Participant weight (kg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Start GnRH antagonist </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> No. of embryos transferred</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Poor responders</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0001" title="DevroeyP , FauserBC , PlatteauP , BeckersNG , DhontM , MannaertsBM . Induction of multiple follicular development by a single dose of long‐acting recombinant follicle‐stimulating hormone (FSH‐CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. Journal of Clinical Endocrinology and Metabolism May;89(5):2062‐70. NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702195 (accessed 18 June 2008). NCT00702195 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during phase II clinical trials for the development of Org 36286 (corifollitropin alfa). www.clinicalstudyresults.org (accessed 27 May 2009). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. clinicaltrials.gov/show/NCT00702806 (accessed 18 June 2008). NCT00702806 . A phase III, open‐label, prospective, randomized, comparative clinical trial to investigate the appropriate dose of a single injection of Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or IVF/ICSI. www.clinicalstudyresults.org (accessed 11 February 2008). ">Devroey 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Leading follicle ≥ 14 mm</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0002" title="BehrB , HeijnenE . Corifollitropin alfa versus recombinant FSH treatment for COS in a GnRH antagonist protocol: equal efficacy in terms of oocyte and embryo quality. Human Reproduction, European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1 2009; Amsterdam, The Netherlands. 2009. BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. BoostanfarR , DevroeyP , OberyeJ , MannaertsB . No difference in the cumulative pregnancy rates or live birth rates when comparing corifollitropin alfa with daily rFSH treatment for COS. Human Reproduction. Abstracts of the 26th Annual Meeting of ESHRE; 2010 June 27‐30; Rome. 2010; Vol. 25 Suppl 1(6):i47 Abstract no. O‐119. BoostanfarR , MannartsB , WitjesH , DevroeyP . International differences in IVF live birth rates and ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility, Annual Meeting of the American Society for Reproductive Medicine. 2011 Oct 15‐19; Orlando2011;96(Suppl 3):174. DevroeyP , BoostanfarR , KoperNP , MannaertsBM , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. Erratum: A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2014;29(5):1116‐1120. DevroeyP , BoostanfarR , KoperNP , MannaertsBMJL , Ijzerman‐BoonPC , FauserBC , ENGAGE Investigators. A double‐blind, non‐inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Human Reproduction2009;24(12):3063‐72. FatemiHM , DoodyK , WitjesH , MannaertsB . A high ovarian response does not compromise the change of pregnancy. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, suppl 1:i319 Abstract no. P‐510. FauserBC , AlperMM , LedgerW , SchoolcraftWB , ZandvlietA , MannaertsBM , Engage Investigators. Pharmacokinetics and follicular dynamics of corifollitropin alfa versus recombinant FSH during ovarian stimulation for IVF. Reproductive BioMedicine Online2010;21(5):593‐601. Fernandez SanchezM , KoperN . Equally high ongoing pregnancy rates with corifollitropin alfa and recombinant FSH irrespective of variations in ART procedures. Human Reproduction, Abstracts of the 26th Annual Meeting of ESHRE; 2009 June 28‐July 1; Amsterdam, The Netherlands. 2009; Vol. 24 Suppl 1:i2 O‐005 Oral. HillensjoT , YekoT , WitjesH , ElbersJ , DevroeyP . Does treatment flexibility affect clinical outcome of either corifollitropin alfa or daily regimens?. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011; Vol. 26, issue suppl 1:i303‐4 Abstract no. P468. LeaderA , PangS , WitjesH , GordonK , DevroeyP . Reduction of daily rFSH dose from stimulation day 8 onward in a corifollitropin alfa or rFSH treatment regimen does not compromise clinical outcome. Human Reproduction, 27th Annual Meeting of the European Society of Human Reproduction and Embryology, ESHRE. Stockholm, Sweden, 2011:i302 Abstract no. P‐465. NCT00698800 . A phase III, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00698800 (accessed 11 June 2008). NCT00698800 . A phase III, randomised, double‐blind, active‐controlled, non‐inferiority clinical trial to investigate the efficacy and safety of a single injection of 150 μg Org 36286 (corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. clinicaltrials.gov/show/NCT00702273 (accessed 18 June 2008). NCT00702273 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 38819. www.clinicalstudyresults.org (accessed 16 February 2010). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 (P05787) for ORG 36286 (Corifollitropin alfa). www.clinicalstudyresults.org (accessed 7 July 2009). NCT00703014 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in Clinical Trial 38819 for ORG 36286 (Corifollitropin alfa). clinicaltrials.gov/show/NCT00703014 (accessed 18 June 2008). ">ENGAGE 2009</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 60 and ≤ 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0003" title="BonduelleM , MannaertsB , LeaderA , BerghC , PassierD , DevroeyP . Prospective follow‐up of 838 fetuses conceived after ovarian stimulation with corifollitropin alfa: comparative and overall neonatal outcome. Human Reproduction2012;27(7):2177‐85. Corifollitropin alfa Ensure Study Group: Obruca A, SchenkM , TewsG , MardesicT , MrazekM , MeinertzH , et al. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower‐body‐weight women. Reproductive BioMedicine Online2010;21(1):66‐76. HillenjsoT , VonMauwE . A comparison of corifollitropin vs. recombinant FSH in a GnRH antagonist protocol for controlled ovarian stimulation in women weighing 60 kg or less. Human Reproduction. European Society of Human Reproduction and Embryology, ESHRE 25th Annual Meeting; 2009 June 28‐July 1; Amsterdam. 2009; Vol. 24 Suppl 1:i2. NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012. clinicaltrials.gov/show/NCT00702546 (accessed 18 June 2008). NCT00702546 . Follow‐up protocol to collect the outcome of frozen‐thawed embryo transfer cycles after cryopreservation of embryos in clinical trial 107012 (P05711). www.clinicalstudyresults.org(accessed November 2009). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702624 (accessed 18 June 2008). NCT00702624 . Pregnancy and neonatal follow‐up of ongoing pregnancies established after controlled ovarian stimulation in clinical trial 107012 for the development of Org 36286 (corifollitropin alfa) (107014/P05710). www.clinicalstudyresults.org (accessed 9 June 2009). NCT00702845 . A phase III, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for ovarian stimulation using daily recombinant FSH as reference. clinicaltrials.gov/show/NCT00702845 (accessed 18 June 2008). NCT00702845 . A phase III, randomized, double‐blind, active‐controlled, equivalence clinical trial to investigate the efficacy and safety of a single injection of 100 μg Org 36286 (Corifollitropin alfa) to induce multifollicular development for controlled ovarian stimulation (COS) using daily recombinant FSH (rFSH) as a reference. www.clinicalstudyresults.org (accessed 11 July 2008). ">ENSURE 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 or 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0004" title="Corifollitropin Alfa Dose‐finding Study Group: Abyholm T, AndersonAN , BalenAH , BraatDDM , DevroeyP , D'HoogeTH , et al. A randomized dose‐response trial of a single injection of corifollitropin alfa to sustain multifollicular growth during controlled ovarian stimulation. Human Reproduction2008;23(11):2484‐92. NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. clinicaltrials.gov/show/NCT005982088 (accessed 10 January 2008). NCT005982088 . A phase 2, open label, randomized trial to investigate the dose‐response relationship of a single injection or Org 36286 (corifollitropin alfa) to initiate multiple follicular growth in a controlled ovarian hyperstimulation protocol for IVF or ICSI. www.clinicalstudyresults.org (accessed 11 July 2008). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during a previous clinical trial for the development of Org 36286 (corifollitropin alfa) (38827/P06056). www.clinicalstudyresults.org (accessed 28 May 2009). NCT00702988 . Pregnancy and neonatal follow‐up of ongoing pregnancies established during clinical trial 38826 for the development of Org 36286 (corifollitropin alfa). clinicaltrials.gov/show/NCT00702988 (accessed 18 June 2008). ">Koper 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 to 39</p> <p>Protocol: 18 to 39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 to 31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0005" title="BoostanfarR , MannaertsB , PangS , Fernandez‐SanchezM , WitjesH , DevroeyP , Engage Investigators. A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle‐stimulating hormone. Fertility and Sterility2012;97(6):1351‐8. BoostanfarR , MannaertsB , WitjesH , DevroeyP . International differences in IVF live birth rates and cumulative ongoing pregnancy rates following ovarian stimulation with corifollitropin alfa or recombinant FSH. Fertility and Sterility2011;1:S174. BoostanfarR , YekoT , ShapiroB , ElbersJ , WitjesH , MannaertsB . A large double‐blind efficacy and safety trial of corifollitropin alfa versus daily recombinant FSH in women 35 to 42 years of age undergoing ovarian stimulation prior to IVF or ICSI (pursue trial). Fertility and Sterility2012;98(Suppl 1):S34. NCT01144416 . A Phase III, Randomized, Double‐blind, Active‐controlled, Non‐inferiority Trial to Investigate the Efficacy and Safety of a single injection of SCH 900962 (Corifollitropin alfa) to Induce Multifollicular Development for Controlled Ovarian Stimulation (COS) Using Daily Recombinant FSH (recFSH) as a Reference in Women aged 35‐42 Years (P06029). clinicaltrials.gov/show/ NCT01144416 (accessed 11 June 2010). NCT01144416 . Efficacy and safety study of a single injection of SCH 900962 versus daily recFSH injections in women undergoing controlled ovarian stimulation (study P06029 AM1) (PURSUE). clinicaltrials.gov/show/NCT01144416 (accessed 11 November 2013). StegmannB , BonduelleM , GordonK , WitjesH , VerweijP . Incidence of congenital malformations after ovarian stimulation with corifollitropin alfa or recombinant FSH: Data from 3 randomized controlled trials. Fertility and Sterility2013;100(3):S59. ">Pursue 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 to 42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Day 5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009577-bbs2-0006" title="NCT01319695 . Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women undergoing in vitro fertilisation. clinicaltrials.gov/show/NCT01319695 (accessed 8 March 2011). SioulasV , SiristatidisC , ChreliasC , AlexiouE , VrantzaT , KassanosD . Corifollitropin alfa vs. recombinant follicle stimulating hormone in ovarian stimulation of women undergoing in vitro fertilization: Preliminary results. Fertility and Sterility. 2011; Vol. 96 Suppl:S181 P‐252. ">Sioulas 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 to 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 to 90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both agonist and antagonist protocol used, day not stated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/full#CD009577-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009577-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting FSH (all doses) versus daily FSH</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.52, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.90, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 High dose (240 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.12, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.74, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.56, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.68, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 High dose (240 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.09, 32.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.86, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.59, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 High dose (240 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.18, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.59, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.87, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Multiple pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.89, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>645</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.52, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.90, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 High dose (240 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.05, 23.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.74, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.38, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.71, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Ectopic pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.42, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.31, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 High dose (240 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Congenital malformation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.16, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Major congenital malformation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.55, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.14, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.55, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Minor congenital malformation rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.72, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Low dose (60 to 120 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Medium dose (150 to 180 μg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.43]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Long‐acting FSH (all doses) versus daily FSH</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009577.pub3/references#CD009577-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009577.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009577-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009577-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009577-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009577\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009577\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009577\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009577\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009577\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009577.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009577.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009577.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009577.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009577.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714721625"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009577.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714721629"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009577.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7592ec9e937d',t:'MTc0MDcxNDcyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 